Cost Analysis. Which Glp based medication is the best bang for the buck?
- Jan 28
- 2 min read
Updated: Feb 23
Many insurance companies are not paying for anti-obesity medications (AOM). There is a current Medicare law that directly affect Medicare patients. This law also indirectly influences other health insurance carriers. In some instances this can be overcome by treatment for a weight/obesity related condition.
For patient patients wanting to start AOM with GLP, we completed a cost analysis based on the SURMOUNT 5 data and using prices from Eli Lilly direct prescriptions of Tirzepatide (Zepbound) vs Costco direct cost of Semaglutide (Wegovy).
From SURMOUNT-5 (approximate, group averages):
Tirzepatide: ~20.2% weight loss
Semaglutide: ~13.7% weight loss
For simplicity we’ll:
Assume full dose price every month for 18 months.
Compare total cost, then calculate cost per % weight loss.
If you want “cost per kg lost” instead, I can add that too — just share an average baseline weight (e.g., 100 kg).
💰 Medication Pricing (Monthly)
Tirzepatide (ZEPBOUND)
Dose | Monthly Cost |
2.5 mg | $299 |
5 mg | $399 |
7.5 mg | $449 |
10 mg | $449 |
12.5 mg | $449 |
15 mg | $449 |
Semaglutide (Wegovy)
Dose | Monthly Cost |
0.25 mg | $199 |
0.5 mg | $199 |
1 mg | $349 |
1.7 mg | $349 |
2.4 mg | $349 |
Estimated Cost per Pound Lost
(12 Months)
Tirzepatide
Dose | 12-Mo Cost | Est. Lbs Lost | Cost per lb Lost |
2.5 mg | $3,588 | ~36.2 lbs | ~$99/lb |
5 mg | $4,788 | ~36.2 lbs | ~$132/lb |
7.5–15 mg | $5,388 | ~36.2 lbs | ~$149/lb |
Semaglutide
Dose | 12-Mo Cost | Est. Lbs Lost | Cost per lb Lost |
0.25/0.5 mg | $2,388 | ~23.8 lbs | ~$100/lb |
1/1.7/2.4 mg | $4,188 | ~23.8 lbs | ~$176/lb |
🧠 What This Tells Us
📉 Estimated Cost per Pound Lost (12 Months)
Tirzepatide 2.5 mg (~$99/lb) may be the most cost effective with possibilities for weight loss. It should be noted that this is usually a titration dose.
👉 Price vs outcome trade-off is important: more weight loss costs more, but can be more cost-efficient for the clinically effective doses. This may be an indication to favor Tirzepatide over semaglutdie.